223 related articles for article (PubMed ID: 17557084)
1. FDA likely to further restrict erythropoietin use for cancer patients.
Fox JL
Nat Biotechnol; 2007 Jun; 25(6):607-8. PubMed ID: 17557084
[No Abstract] [Full Text] [Related]
2. Erythropoietin, the FDA, and oncology.
Steinbrook R
N Engl J Med; 2007 Jun; 356(24):2448-51. PubMed ID: 17568025
[No Abstract] [Full Text] [Related]
3. What ails the FDA?
Jenny-Avital ER
N Engl J Med; 2005 Jun; 352(24):2554-5. PubMed ID: 15962407
[No Abstract] [Full Text] [Related]
4. Perspectives. Approval process a moving target in FDA reform hearings.
Rhein R
Faulkner Grays Med Health; 1996 Feb; 50(8):suppl 1-4. PubMed ID: 10154482
[No Abstract] [Full Text] [Related]
5. FDA embraces risk-management approach.
Fox JL
Nat Biotechnol; 2003 Oct; 21(10):1120-1. PubMed ID: 14520383
[No Abstract] [Full Text] [Related]
6. The drive to reform the FDA gains momentum.
Gatty B
Hosp Formul; 1995 Mar; 30(3):178, 177. PubMed ID: 10141250
[No Abstract] [Full Text] [Related]
7. Who would approve new drugs if there were no FDA?
Gatty B
Hosp Formul; 1995 Jan; 30(1):58, 57. PubMed ID: 10139726
[No Abstract] [Full Text] [Related]
8. The big gap at the FDA.
Stipp D
Fortune; 2002 Jul; 146(2):113-4, 116. PubMed ID: 12141178
[No Abstract] [Full Text] [Related]
9. Muddied messages about FDA.
Miller HI
Nat Biotechnol; 2003 Jul; 21(7):732-3. PubMed ID: 12833084
[No Abstract] [Full Text] [Related]
10. FDA restructures new product review centers.
Bouchie A
Nat Biotechnol; 2002 Oct; 20(10):960. PubMed ID: 12355100
[No Abstract] [Full Text] [Related]
11. Trouble at the FDA: can we fix the problems affecting you and your patients?
Henley E
J Fam Pract; 2006 Apr; 55(4):301-4. PubMed ID: 16608668
[No Abstract] [Full Text] [Related]
12. New office and new leader aim to streamline FDA cancer drug review process.
Twombly R
J Natl Cancer Inst; 2005 May; 97(10):708-9. PubMed ID: 15900036
[No Abstract] [Full Text] [Related]
13. Should you let the FDA decide what drugs you pay for?
Dutton G
Bus Health; 1996 Oct; 14(10):65, 69-70, 73. PubMed ID: 10161492
[No Abstract] [Full Text] [Related]
14. FDA appointee faces angry, demoralized staff.
Fox JL
Nat Biotechnol; 2002 Nov; 20(11):1065. PubMed ID: 12410237
[No Abstract] [Full Text] [Related]
15. FDA and EMEA pool scientific advice.
Katsnelson A
Nat Biotechnol; 2004 Dec; 22(12):1490-1. PubMed ID: 15583642
[No Abstract] [Full Text] [Related]
16. FDA reorganization inspires hope for better coordination.
May M
Nat Med; 2011 Sep; 17(9):1024. PubMed ID: 21900900
[No Abstract] [Full Text] [Related]
17. A Food and Drug Administration primer.
Simon LS
Arthritis Rheum; 2006 Feb; 55(1):4-8. PubMed ID: 16463403
[No Abstract] [Full Text] [Related]
18. Sweeping changes to Food and Drug Administration and drug safety regulations.
Cross JT
Arch Intern Med; 2007 Apr; 167(7):732. PubMed ID: 17420439
[No Abstract] [Full Text] [Related]
19. Avoiding the regulatory capture of the Food and Drug Administration.
Egilman DS; Presler AH; Valentin CS
Arch Intern Med; 2007 Apr; 167(7):732-3. PubMed ID: 17420438
[No Abstract] [Full Text] [Related]
20. What ails the FDA?
Cohen FJ
N Engl J Med; 2005 Jun; 352(24):2554. PubMed ID: 15962406
[No Abstract] [Full Text] [Related]
[Next] [New Search]
